Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 130

Results For "Active"

1360 News Found

DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
Biotech | August 24, 2021

DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial

CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study


Pfizer receives EC approval for XEIJANZ
Biotech | August 23, 2021

Pfizer receives EC approval for XEIJANZ

XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor


Jehangir Hospital launches upgraded centre for Endoscopy
Healthcare | August 20, 2021

Jehangir Hospital launches upgraded centre for Endoscopy

The Endosonography allows the use of EUS guided Fine needle aspiration for accurate diagnosis of GI cancers without the need for conventional biopsies


Enzene Biosciences obtains DCGI approval for Romiplostim biosimilar
Biotech | August 20, 2021

Enzene Biosciences obtains DCGI approval for Romiplostim biosimilar

It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)


Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine
Biotech | August 20, 2021

Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine

This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC


Finding a cure for HIV
Drug Approval | August 19, 2021

Finding a cure for HIV

The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.


Suven Life Sciences announces Phase 3 clinical trial of Masupirdine
Biotech | August 17, 2021

Suven Life Sciences announces Phase 3 clinical trial of Masupirdine

This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024


Antiviral face mask capable of inactivating COVID19
News | August 16, 2021

Antiviral face mask capable of inactivating COVID19

The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)


USFDA grants distinct indication for Chronic Sleep Disorder
Drug Approval | August 13, 2021

USFDA grants distinct indication for Chronic Sleep Disorder

Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder


Ind-Swift Laboratories PAT at Rs 18.80 cr for Q1FY22
News | August 13, 2021

Ind-Swift Laboratories PAT at Rs 18.80 cr for Q1FY22

EPS stood at Rs 3.18